title: CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers.
abstract: CXCR4 is a cell membrane receptor that is overexpressed in triple-negative breast cancers and implicated in growth and metastasis of this disease. Using electrohydrodynamic cojetting, we prepared multicompartmental drug delivery carriers for CXCR4 targeting. The particles are comprised of a novel poly(lactide-co-glycolide) derivative that allows for straightforward immobilization of 1,1'-[1,4-phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] (Plerixafor), a small molecule with affinity for CXCR4. Targeted nanocarriers are selectively taken up by CXCR4-expressing cells and effectively block CXCR4 signaling. This study suggests that CXCR4 may be an effective target for nanocarrier-based therapies.
authors.forename: Asish C
authors.initials: AC
authors.lastname: Misra
authors.forename: Kathryn E
authors.initials: KE
authors.lastname: Luker
authors.forename: Hakan
authors.initials: H
authors.lastname: Durmaz
authors.forename: Gary D
authors.initials: GD
authors.lastname: Luker
authors.affiliation: §Institute of Functional Interfaces, Karlsruhe Institute of Technology, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany.
authors.forename: Joerg
authors.initials: J
authors.lastname: Lahann
mesh_terms: D001596:Benzylamines; D045744:Cell Line, Tumor; D000080027:Cyclams; D016503:Drug Delivery Systems; D005260:Female; D006571:Heterocyclic Compounds / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D053758:Nanoparticles / Q000008:administration & dosage*; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D001596:Benzylamines; C527276:CXCR4 protein, human; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; C088327:plerixafor